Opus Genetics (NASDAQ:IRD) Receives “Buy” Rating from HC Wainwright

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $8.00 price objective on the stock.

Opus Genetics Stock Down 2.7 %

Shares of NASDAQ IRD opened at $1.10 on Wednesday. The stock has a fifty day moving average of $1.15. The company has a market cap of $34.73 million, a price-to-earnings ratio of -1.01 and a beta of 0.16. Opus Genetics has a 12 month low of $0.81 and a 12 month high of $2.65.

Insider Buying and Selling at Opus Genetics

In other news, CEO George Magrath acquired 100,000 shares of the stock in a transaction on Thursday, December 26th. The stock was acquired at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the transaction, the chief executive officer now owns 599,150 shares of the company’s stock, valued at $587,167. This represents a 20.03 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.60% of the company’s stock.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.